May 25, 2013 8:48 AM ET

Biotechnology

Company Overview of SomaLogic, Inc.

Company Overview

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic, Inc. was founded in 1999 and is headquartered in Boulder, C...

Detailed Description

2945 Wilderness Place

Boulder, CO 80301

United States

Founded in 1999

Phone:

303-625-9000

Fax:

303-545-2525

www.somalogic.com

Key Executives for SomaLogic, Inc.

Founder
Age: 70
Chief Financial Officer
Chief Medical Officer Emertius
Age: 73
Chief Science Officer
Age: 51
Chief Medical Officer
Age: 53
Compensation as of Fiscal Year 2012.

SomaLogic, Inc. Key Developments

SomaLogic, Inc. Announces Research Agreement with Novartis to Accelerate Pharmaceutical Discovery and Development

SomaLogic, Inc. announced that it has entered into a multi-year research agreement with Novartis AG to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts. SomaLogic's proprietary proteomic platform is built on two decades of painstaking work to develop an entirely new generation of specific protein-binding reagents that would break open protein biomarker discovery and development in order to drive new diagnostic and therapeutic opportunities. SOMAmers offer a uniquely powerful combination of specific binding to individual proteins and facile nucleic acid-based quantification, allowing accurate detection and measurement of literally thousands of proteins over a vast range of concentrations in just a few drops of blood or other tissues.

SomaLogic, Inc. and New England Biolabs, Inc. Enter into an Exclusive Licensing Agreement

SomaLogic, Inc. and New England Biolabs, Inc. announced that they have entered into an exclusive licensing agreement whereby SomaLogic will provide specific SOMAmers as critical and unique reagents in several current and future NEB nucleic acid amplification and polymerase chain reaction (PCR) products. SOMAmers are specific protein binding reagents based on chemically modified "aptamers," or short single-stranded nucleic acids. Although SOMAmers have nearly unlimited potential in many different proteomic applications, NEB is incorporating specific SOMAmers into their products as reversible inhibitors of thermally active DNA polymerases used in PCR.

Similar Private Companies By Industry

Company Name Region
Varinel, Inc. United States
CerRx Inc. United States
Remedy Pharmaceuticals, Inc. United States
Luna Analytics United States
Warner Chilcott Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SomaLogic, Inc., please visit www.somalogic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.